Should  ||| S:0 E:7 ||| MD
we  ||| S:7 E:10 ||| PRP
target  ||| S:10 E:17 ||| VBP
blood  ||| S:17 E:23 ||| NN
pressure  ||| S:23 E:32 ||| NN
in  ||| S:32 E:35 ||| IN
sepsis ||| S:35 E:41 ||| NN
?  ||| S:41 E:43 ||| .
To  ||| S:43 E:46 ||| TO
review  ||| S:46 E:53 ||| VB
blood  ||| S:53 E:59 ||| NN
pressure  ||| S:59 E:68 ||| NN
targets  ||| S:68 E:76 ||| NNS
and  ||| S:76 E:80 ||| CC
their  ||| S:80 E:86 ||| PRP$
implementation  ||| S:86 E:101 ||| NN
in  ||| S:101 E:104 ||| IN
sepsis ||| S:104 E:110 ||| NN
.  ||| S:110 E:112 ||| .
Review  ||| S:112 E:119 ||| NN
of  ||| S:119 E:122 ||| IN
the  ||| S:122 E:126 ||| DT
hemodynamic  ||| S:126 E:138 ||| JJ
intervention  ||| S:138 E:151 ||| NN
trials  ||| S:151 E:158 ||| NNS
in  ||| S:158 E:161 ||| IN
sepsis ||| S:161 E:167 ||| NN
.  ||| S:167 E:169 ||| .
Explicit  ||| S:169 E:178 ||| JJ
blood  ||| S:178 E:184 ||| NN
pressure  ||| S:184 E:193 ||| NN
targets  ||| S:193 E:201 ||| NNS
have  ||| S:201 E:206 ||| VBP
been  ||| S:206 E:211 ||| VBN
recommended  ||| S:211 E:223 ||| VBN
for  ||| S:223 E:227 ||| IN
septic  ||| S:227 E:234 ||| JJ
patients ||| S:234 E:242 ||| NNS
.  ||| S:242 E:244 ||| .
The  ||| S:244 E:248 ||| DT
Surviving  ||| S:248 E:258 ||| NNP
Sepsis  ||| S:258 E:265 ||| NNP
Guidelines  ||| S:265 E:276 ||| NNS
recommend  ||| S:276 E:286 ||| VBP
vasopressors  ||| S:286 E:299 ||| VBN
to  ||| S:299 E:302 ||| TO
achieve  ||| S:302 E:310 ||| VB
and  ||| S:310 E:314 ||| CC
maintain  ||| S:314 E:323 ||| VB
a  ||| S:323 E:325 ||| DT
mean  ||| S:325 E:330 ||| JJ
arterial  ||| S:330 E:339 ||| JJ
blood  ||| S:339 E:345 ||| NN
pressure  ||| S:345 E:354 ||| NN
of  ||| S:354 E:357 ||| IN
at  ||| S:357 E:360 ||| IN
least  ||| S:360 E:366 ||| JJS
65  ||| S:366 E:369 ||| CD
mm  ||| S:369 E:372 ||| CD
Hg  ||| S:372 E:375 ||| NNS
in  ||| S:375 E:378 ||| IN
patients  ||| S:378 E:387 ||| NNS
not  ||| S:387 E:391 ||| RB
responding  ||| S:391 E:402 ||| VBG
to  ||| S:402 E:405 ||| TO
initial  ||| S:405 E:413 ||| JJ
fluid  ||| S:413 E:419 ||| JJ
resuscitation ||| S:419 E:432 ||| NN
.  ||| S:432 E:434 ||| .
Patients  ||| S:434 E:443 ||| NNS
remaining  ||| S:443 E:453 ||| VBG
hypotensive  ||| S:453 E:465 ||| NN
despite  ||| S:465 E:473 ||| IN
efforts  ||| S:473 E:481 ||| NNS
to  ||| S:481 E:484 ||| TO
increase  ||| S:484 E:493 ||| VB
blood  ||| S:493 E:499 ||| NN
pressure  ||| S:499 E:508 ||| NN
have  ||| S:508 E:513 ||| VBP
up  ||| S:513 E:516 ||| RP
to  ||| S:516 E:519 ||| TO
twice  ||| S:519 E:525 ||| RB
as  ||| S:525 E:528 ||| IN
high  ||| S:528 E:533 ||| JJ
mortality  ||| S:533 E:543 ||| NN
as  ||| S:543 E:546 ||| IN
those  ||| S:546 E:552 ||| DT
whose  ||| S:552 E:558 ||| JJ
hypotension  ||| S:558 E:570 ||| NN
can  ||| S:570 E:574 ||| MD
be  ||| S:574 E:577 ||| VB
corrected  ||| S:577 E:587 ||| VBN
with  ||| S:587 E:592 ||| IN
fluids  ||| S:592 E:599 ||| NNS
and  ||| S:599 E:603 ||| CC
vasopressors ||| S:603 E:615 ||| NN
.  ||| S:615 E:617 ||| .
The  ||| S:617 E:621 ||| DT
actual  ||| S:621 E:628 ||| JJ
blood  ||| S:628 E:634 ||| NN
pressure  ||| S:634 E:643 ||| NN
targets  ||| S:643 E:651 ||| NNS
and  ||| S:651 E:655 ||| CC
their  ||| S:655 E:661 ||| PRP$
implementation  ||| S:661 E:676 ||| NNS
are  ||| S:676 E:680 ||| VBP
the  ||| S:680 E:684 ||| DT
main  ||| S:684 E:689 ||| JJ
determinants  ||| S:689 E:702 ||| NN
of  ||| S:702 E:705 ||| IN
the  ||| S:705 E:709 ||| DT
patient ||| S:709 E:716 ||| NN
's  ||| S:716 E:719 ||| POS
exposure  ||| S:719 E:728 ||| NN
to  ||| S:728 E:731 ||| TO
vasopressors ||| S:731 E:743 ||| VB
.  ||| S:743 E:745 ||| .
Several  ||| S:745 E:753 ||| JJ
randomized  ||| S:753 E:764 ||| NNS
controlled  ||| S:764 E:775 ||| VBN
trials  ||| S:775 E:782 ||| NNS
on  ||| S:782 E:785 ||| IN
hemodynamic  ||| S:785 E:797 ||| JJ
interventions  ||| S:797 E:811 ||| NNS
in  ||| S:811 E:814 ||| IN
septic  ||| S:814 E:821 ||| JJ
shock  ||| S:821 E:827 ||| NN
show  ||| S:827 E:832 ||| NN
that  ||| S:832 E:837 ||| IN
patients  ||| S:837 E:846 ||| NNS
continue  ||| S:846 E:855 ||| VBP
to  ||| S:855 E:858 ||| TO
receive  ||| S:858 E:866 ||| VB
vasopressors  ||| S:866 E:879 ||| VBN
despite  ||| S:879 E:887 ||| IN
the  ||| S:887 E:891 ||| DT
fact  ||| S:891 E:896 ||| NN
that  ||| S:896 E:901 ||| IN
blood  ||| S:901 E:907 ||| NN
pressure  ||| S:907 E:916 ||| NN
targets  ||| S:916 E:924 ||| NNS
have  ||| S:924 E:929 ||| VBP
been  ||| S:929 E:934 ||| VBN
exceeded ||| S:934 E:942 ||| VBN
,  ||| S:942 E:944 ||| ,
and  ||| S:944 E:948 ||| CC
thus  ||| S:948 E:953 ||| RB
vasopressors  ||| S:953 E:966 ||| RB
should  ||| S:966 E:973 ||| MD
be  ||| S:973 E:976 ||| VB
reduced ||| S:976 E:983 ||| VBN
.  ||| S:983 E:985 ||| .
Accordingly ||| S:985 E:996 ||| RB
,  ||| S:996 E:998 ||| ,
patients  ||| S:998 E:1007 ||| NNS
are  ||| S:1007 E:1011 ||| VBP
likely  ||| S:1011 E:1018 ||| JJ
to  ||| S:1018 E:1021 ||| TO
be  ||| S:1021 E:1024 ||| VB
exposed  ||| S:1024 E:1032 ||| VBN
to  ||| S:1032 E:1035 ||| TO
higher  ||| S:1035 E:1042 ||| JJR
amounts  ||| S:1042 E:1050 ||| NNS
of  ||| S:1050 E:1053 ||| IN
vasopressors  ||| S:1053 E:1066 ||| NN
and  ||| S:1066 E:1070 ||| CC
over  ||| S:1070 E:1075 ||| IN
longer  ||| S:1075 E:1082 ||| JJR
periods  ||| S:1082 E:1090 ||| NNS
of  ||| S:1090 E:1093 ||| IN
time  ||| S:1093 E:1098 ||| NN
than  ||| S:1098 E:1103 ||| IN
would  ||| S:1103 E:1109 ||| MD
be  ||| S:1109 E:1112 ||| VB
necessary  ||| S:1112 E:1122 ||| JJ
if  ||| S:1122 E:1125 ||| IN
the  ||| S:1125 E:1129 ||| DT
predefined  ||| S:1129 E:1140 ||| JJ
targets  ||| S:1140 E:1148 ||| NNS
would  ||| S:1148 E:1154 ||| MD
be  ||| S:1154 E:1157 ||| VB
strictly  ||| S:1157 E:1166 ||| RB
implemented ||| S:1166 E:1177 ||| VBN
.  ||| S:1177 E:1179 ||| .
Post  ||| S:1179 E:1184 ||| NNP
hoc  ||| S:1184 E:1188 ||| FW
analyses  ||| S:1188 E:1197 ||| NNS
suggest  ||| S:1197 E:1205 ||| VBP
that  ||| S:1205 E:1210 ||| IN
in  ||| S:1210 E:1213 ||| IN
patients  ||| S:1213 E:1222 ||| NNS
without  ||| S:1222 E:1230 ||| IN
refractory  ||| S:1230 E:1241 ||| JJ
hypotension ||| S:1241 E:1252 ||| NN
,  ||| S:1252 E:1254 ||| ,
the  ||| S:1254 E:1258 ||| DT
cumulative  ||| S:1258 E:1269 ||| JJ
vasopressor  ||| S:1269 E:1281 ||| JJ
load  ||| S:1281 E:1286 ||| NN
is  ||| S:1286 E:1289 ||| VBZ
independently  ||| S:1289 E:1303 ||| RB
associated  ||| S:1303 E:1314 ||| VBN
with  ||| S:1314 E:1319 ||| IN
mortality ||| S:1319 E:1328 ||| NN
.  ||| S:1328 E:1330 ||| .
Accordingly ||| S:1330 E:1341 ||| RB
,  ||| S:1341 E:1343 ||| ,
reduction  ||| S:1343 E:1353 ||| NN
of  ||| S:1353 E:1356 ||| IN
exposure  ||| S:1356 E:1365 ||| NN
to  ||| S:1365 E:1368 ||| TO
vasopressors  ||| S:1368 E:1381 ||| NN
has  ||| S:1381 E:1385 ||| VBZ
the  ||| S:1385 E:1389 ||| DT
potential  ||| S:1389 E:1399 ||| NN
of  ||| S:1399 E:1402 ||| IN
improving  ||| S:1402 E:1412 ||| VBG
outcomes ||| S:1412 E:1420 ||| NNS
.  ||| S:1420 E:1422 ||| .
This  ||| S:1422 E:1427 ||| DT
can  ||| S:1427 E:1431 ||| MD
be  ||| S:1431 E:1434 ||| VB
achieved  ||| S:1434 E:1443 ||| VBN
by  ||| S:1443 E:1446 ||| IN
adhering  ||| S:1446 E:1455 ||| VBG
to  ||| S:1455 E:1458 ||| TO
the  ||| S:1458 E:1462 ||| DT
lower  ||| S:1462 E:1468 ||| RBR
currently  ||| S:1468 E:1478 ||| RB
proposed  ||| S:1478 E:1487 ||| VBN
blood  ||| S:1487 E:1493 ||| NN
pressure  ||| S:1493 E:1502 ||| NN
limits ||| S:1502 E:1508 ||| NNS
.  ||| S:1508 E:1510 ||| .
In  ||| S:1510 E:1513 ||| IN
addition ||| S:1513 E:1521 ||| NN
,  ||| S:1521 E:1523 ||| ,
the  ||| S:1523 E:1527 ||| DT
lowest  ||| S:1527 E:1534 ||| JJS
tolerable  ||| S:1534 E:1544 ||| JJ
blood  ||| S:1544 E:1550 ||| NN
pressure  ||| S:1550 E:1559 ||| NN
levels  ||| S:1559 E:1566 ||| NNS
should  ||| S:1566 E:1573 ||| MD
be  ||| S:1573 E:1576 ||| VB
reevaluated ||| S:1576 E:1587 ||| NNS
.  ||| S:1587 E:1589 ||| .
